Tavor

Anxiety

Rakitzi, StavroulaPhase 1Active

CC

41/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 81/ 100

Competitive context

18 Active assets in the Anxiety cohort.

Asset / Sponsor	Phase	Rating
Cipralex Wake Forest University Health Sciences	Phase 4	BB
MIDAZOLAM Theresa Jacob, PhD, MPH	Phase 4	BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE RIVER Foundation	Phase 4	BB
NEPENTHE Istituti Clinici Scientifici Maugeri SpA	Phase 4	BB
CITALOPRAM Hannover Medical School	Phase 4	BB

View all 34 →

Same molecule, other indications

Tavor is also rated in:

bipolar disorderDormant

BB

Indicative ·

65 / 100

Bipolar DisorderDormant

B

Indicative ·

63 / 100

treatment-refractory schizophreniaDormant

B

Indicative ·

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.